Lanib 4 mg (Capsule)
Unit Price: ৳ 600.00 (3 x 10: ৳ 18,000.00)
Strip Price: ৳ 6,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Drug international ltd |
Indications
- Differentiated Thyroid Cancer treatment
- Renal Cell Carcinoma treatment
- Hepatocellular Carcinoma treatment
- Endometrial Carcinoma treatment
Pharmacology
- Kinase inhibitor: VEGFR1, VEGFR2, VEGFR3, FGFR1-4, PDGFR, KIT, RET
- Absorption: Takes 1-4 hours to reach peak plasma concentration
- Distribution: Binds to human plasma proteins (98-99%)
- Metabolism: Processed by CYP3A and aldehyde oxidase
- Excretion: 64% eliminated in feces, 25% in urine
- Elimination half-life: Approx. 28 hours
Dosage
- Dose reduction for patients with renal or hepatic impairment
- Differentiated Thyroid Cancer: 24 mg orally once daily
- Renal Cell Carcinoma: 18 mg + 5 mg Everolimus orally once daily
- Hepatocellular Carcinoma: 12 mg for ≥60 kg, 8 mg for <60 kg orally once daily
- Endometrial Carcinoma: 20 mg orally once daily + Pembrolizumab 200 mg intravenous infusion every 3 weeks
Administration
- Swallow capsules whole or dissolve in liquid
- Can be taken with or without food
Drug Interaction
- Avoid coadministration with drugs prolonging QT interval
Contraindications
- Hypersensitivity to Lenvatinib or any components
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure/impairment
- Proteinuria
- Diarrhea
- Fistula formation/gastrointestinal perforation
- QT interval prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Can cause embryo-fetal harm
- Females should use effective contraception during treatment
- Not known if excreted in human milk, discontinue breastfeeding
Precautions & Warnings
- Monitor blood pressure regularly
- Monitor for signs of cardiac dysfunction
- Permanently discontinue after arterial thrombotic event
- Regular liver function monitoring
- Monitor for proteinuria
- Promptly manage diarrhea
- Permanently discontinue for gastrointestinal perforation/fistula
- Monitor and correct electrolyte abnormalities
- Consider risk of severe/fatal hemorrhage
- Monitor thyroid function regularly
Special Populations
- Dosage modification for severe renal impairment
- Dosage modification for severe hepatic impairment
- Not established for pediatric use
Overdose Effects
- Not expected to be dialyzable
- Death reported with single dose of 120 mg
Storage Conditions
- Store below 30°C in a dry place
- Protect from light
- Keep out of the reach of children